Haystack MRD Test

Better clinical development with better MRD testing

Unmatched sensitivity and specificity for confident MRD detection. Arriving Soon.

For Biopharma

Haystack MRD™ leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma initiatives like no other minimal residual disease (MRD) test.

01
Adjuvant setting
Stratify patients and enrich for ctDNA-positive patients for adjuvant-setting enrollment
02
Therapeutic monitoring

Follow response more deeply for a complete picture of therapeutic efficacy

03
Second-line treatment

Identify adjuvant therapy nonresponders more quickly for second-line therapy to control progression sooner

Click to enlarge

Quick View

Haystack MRD Test

Haystack MRD™ is a tumor-informed liquid-biopsy-based test that begins with tissue-based whole-exome sequencing (WES) to identify patient-specific tumor mutations. A personalized MRD test is then developed to detect ctDNA from residual, recurrent, or resistant disease.

clinicians-timeline

Click to enlarge

HS-grid-items (2)
HS-grid-items (1)

Analytical performance details

Sensitive and accurate ctDNA detection

Haystack MRD is powered by Haystack Duo™ chemistry to achieve sensitivity down to 1 part per million (1 PPM, or 0.0001% tumor fraction) with 100% specificity observed.

Click to enlarge

Confident MRD calls

Haystack MRD delivers exceptional accuracy at ultra-low ctDNA levels. The test's clean background allows the calling threshold to be set lower than other methods, which yields the highest sensitivity for patient enrollment, stratification, and response monitoring.

Click to enlarge

Click to enlarge

The multi-tool of MRD

Unlike other tests, Haystack MRD was purpose-built for granular ctDNA testing that reports variant-level results. So besides reporting sample-level MRD status, Haystack MRD can track specific ctDNA variants for various applications including targeted therapy guidance.

Each patient’s whole genome library is also archived and is available for acquired resistance mapping and retrospective genomic discovery.

Click to enlarge

Click to enlarge

HS-grid-items (1)
middle-aged-man-pondering middle-aged-man-pondering-hover

Contact Us

Get in touch

With our deep roots in liquid biopsy and MRD testing, Haystack Oncology is committed to providing biopharma solutions to improve patient outcomes. Let our unmatched MRD detection capabilities and team of global experts support your clinical cancer research and therapeutic development efforts.

Have questions? We would love to hear from you. Simply click the button below.